The Correlation between Visceral Fat Area in Patients with Type 2 Diabetes and Obesity and Glycolipid Metabolism
-
摘要:
目的 探讨2型糖尿病(type 2 diabetes mellitus,T2DM)患者不同程度内脏脂肪面积与肥胖相关指标及糖脂代谢指标的相关性。 方法 选取2017年10月至2018年9月就诊于昆明医科大学第二附属医院的682例T2DM患者纳入研究,通过内脏脂肪检测仪(DUALSCAN HDS-2000)检测内脏脂肪面积(visceral fat area,VFA)并按VFA 0~50 cm2、50~100 cm2、100~150 cm2、≥150 cm2分为A、B、C、D 4组。比较4组腰围、BMI、腹部皮下脂肪面积、胰岛素(INS)及C-肽(C-P)释放试验、尿酸(UA)、血脂、HCY、胱抑素C(Cysc)的差异并分析相关性,以探讨2型糖尿病患者VFA与各检测指标的关系的相关性。 结果 内脏脂肪面积与腰围、BMI、腹部皮下脂肪面积呈正相关(r > 0,P < 0.05)。A、B、C、D 4组INS(0 h、1 h、2 h)、C-P(0 h、1 h、2 h)、UA水平依次递增(P < 0.05),VFA与INS(0 h、1 h、2 h、3 h),C-P(0 h、1 h)、TG、APOE、UA、CYSC均呈正相关(r > 0,P < 0.05)。 结论 2型糖尿病患者VFA与肥胖、胰岛素抵抗、甘油三酯、尿酸、CYSC呈正相关。 Abstract:Objective To explore the relationship between the different degrees of visceral fat area and obesity indexes and glycolipid metabolism indexes in type 2 diabetes patients. Methods From October 2017 to September 2018, 682 T2DM patients admitted to the Endocrinology Department of the 2nd Affiliated Hospital of Kunming Medical University were included in this study. The visceral fat area (VFA) was measured by the visceral fat detector (DUALSCAN HDS-2000) and divided into group A, B, C and D according to VFA 0~50 cm2, 50~100 cm2, 100~150 cm2 and ≥150 cm2. The differences of waist circumference, BMI, abdominal subcutaneous fat area, insulin (INS) and C-peptide (C-P) release test, uric acid (UA), blood lipid, HCY, Cystatin C (Cysc) in the four groups were compared and the correlation was analyzed. Results There was a positive correlation between the visceral fat area and obesity-related indicators (r >, P < 0.05). VFA was positively correlated with INS(0 h, 1 h, 2 h, 3 h), C-P (0 h, 1 h), TG, APOE, UA, CYSC (r > 0, P < 0.05). Conclusion VFA is positively correlated with obesity, insulin resistance, triglyceride, uric acid and CYSC in patients with type 2 diabetes. The greater the VFA, the more severe the degree of obesity and insulin resistance, and the higher the blood uric acid and triglyceride. -
Key words:
- Type 2 Diabetes Mellitus /
- Visceral fat area /
- Lipid metabolism /
- Glucose homeostasis /
- Obesity
-
表 1 4组年龄、性别、病程比较
Table 1. Comparison of age,sex and course of disease in the four groups
指标 A组(n = 70) B组(n = 373) C组(n = 209) D组(n = 30) F/χ2/H P 年龄(岁) 53.44 ± 10.04 54.70 ± 9.54 55.26 ± 10.42 49.63 ± 12.23 3.082 0.27 性别(男/女) 45/25 242/134 138/71 21/9 0.400 0.94 病程(a) 6(1.8,10.0) 5(0.5,10.0) 5(0.9,10.0) 5.5(0.8,12.3) 1.686 0.64 表 2 4组腰围、BMI、皮下脂肪面积情况比较(
$\bar{x} \pm s$ )Table 2. Comparison of waist circumference,BMI and subcutaneous fat area in the four groups (
$\bar{x} \pm s$ )指标 A组(n=70) B组(n=373) C组(n=209) D组(n=30) F P 腰围(cm) 84.09 ± 8.98△▲ 88.60 ± 8.02▲ 96.81 ± 7.05 105.20 ± 12.88*△▲ 76.279 < 0.001 BMI(cm/kg2) 21.96 ± 2.79△▲ 23.86 ± 2.37▲ 26.73 ± 2.87 30.03 ± 4.4*△▲ 114.873 < 0.001 腹部皮下脂肪面积(cm2) 98.15 ± 33.80△▲ 141.22 ± 41.06▲ 183.95 ± 56.22 255.89 ± 90.44*△▲ 109.778 < 0.001 与A组比较,*P < 0.05;与B组比较,△P < 0.05;与C组比较,▲P < 0.05。 表 3 4组胰岛素、C-肽释放实验比较(
$\bar{x} \pm s$ )Table 3. Comparison of insulin and C-peptide release experiments in the four groups (
$\bar{x} \pm s$ )指标 A组(n = 70) B组(n = 373) C组(n = 209) D组(n = 30) F P 0 h INS(uIU/L) 8.23 ± 2.08△▲ 10.24 ± 2.73▲ 14.26 ± 4.86 18.75 ± 2.25*△▲ 22.514 < 0.001 1 h INS(uIU/L) 26.67 ± 2.93△▲ 29.89 ± 1.15▲ 37.91 ± 1.8 46.66 ± 7.18*△▲ 9.372 < 0.001 2 h INS(uIU/L) 29.76 ± 3.64△▲ 38.80 ± 1.80▲ 49.84 ± 2.85 67.29 ± 11.62*△▲ 10.528 < 0.001 3 h INS(uIU/L) 24.69 ± 2.68 34.43 ± 3.34 39.83 ± 2.10 50.01 ± 8.09 2.351 0.071 0 h C-P(ng/mL) 2.10 ± 1.56△▲ 2.36 ± 1.49▲ 2.75 ± 1.31 3.47 ± 1.91*△▲ 9.180 < 0.001 1 h C-P(ng/mL) 3.54 ± 0.41△▲ 3.68 ± 2.13▲ 4.09 ± 2.22 5.04 ± 2.98*△▲ 4.336 0.005 2 h C-P(ng/mL) 4.71 ± 2.24△▲ 5.24 ± 3.34▲ 5.72 ± 3.48 6.86 ± 2.44*△▲ 3.392 0.018 3 h C-P(ng/mL) 4.36 ± 1.15 5.54 ± 2.34 7.07 ± 4.58 5.51 ± 2.24 1.933 0.123 与A组比较,*P < 0.05;与B组比较,△P < 0.05;与C组比较,▲P < 0.05。 表 4 4组血脂、HCY、NEFA、CYSC等代谢指标情况比较(
$\bar{x} \pm s$ )Table 4. Comparison of lipid,Hcy,NEFA,Cysc and other metabolic indexes in the four groups (
$\bar{x} \pm s$ )指标 A组(n = 70) B组(n = 373) C组(n = 209) D组(n = 30) F P TC(mmol/L) 4.66 ± 1.31 4.62 ± 1.34 4.64 ± 1.18 5.23 ± 3.90 1.575 0.194 TG(mmol/L) 2.16 ± 0.27 2.76 ± 0.74 2.99 ± 0.18 3.30 ± 0.54 1.255 0.289 HDL-C(mmol/L) 0.68 ± 0.08 1.19 ± 0.45 1.24 ± 0.07 1.16 ± 0.48 0.547 0.650 LDL-C(mmol/L) 2.90 ± 0.89 2.91 ± 0.95 2.91 ± 0.82 2.98 ± 0.91 0.053 0.984 脂蛋白α(mg/dL) 16.95 ± 2.17 15.24 ± 8.30 14.51 ± 8.39 13.17 ± 6.94 0.404 0.750 APOA1(g/L) 1.33 ± 0.28 1.33 ± 0.58 1.30 ± 0.25 1.23 ± 0.26 0.551 0.648 APOB(g/L) 0.93 ± 0.28 0.92 ± 0.25 0.95 ± 0.24 0.87 ± 0.29 0.998 0.393 APOE(mg/dL) 4.16 ± 1.77 4.46 ± 2.70 4.64 ± 1.95 5.33 ± 2.65 1.626 0.182 CYSC(mg/L) 0.96 ± 0.06 1.02 ± 0.46 0.89 ± 0.19 1.02 ± 0.30 0.159 0.924 NEFA(umol/L) 528.85 ± 296.31 567.51 ± 271.37 560.55 ± 288.61 694.52 ± 62.67 2.131 0.095 HCY(umol/L) 15.05 ± 5.58 15.12 ± 6.29 15.85 ± 10.37 15.21 ± 7.64 0.433 0.730 UA(umol/L) 327.43 ± 116.80▲ 354.34 ± 112.67▲ 375.30 ± 109.35 386.92 ± 136.58*△▲ 4.090 0.007* 与A组比较,*P < 0.05;与B组比较,△P < 0.05;与C组比较,▲P < 0.05。 -
[1] Collaboration N C D R F. Worldwide trends in diabetes since 1980:a pooled analysis of 751 population-based studies with 4.4 million participants[J]. Lancet,2016,387(10027):1513-1530. doi: 10.1016/S0140-6736(16)00618-8 [2] Yoon K H,Lee J H,Kim J W,et al. Epidemic obesity and type 2 diabetes in Asia[J]. Lancet,2006,368(9548):1681-1688. doi: 10.1016/S0140-6736(06)69703-1 [3] Hayashi T,Boyko E J,leonetti D L,et al. Visceral adiposity and the risk of impaired glucose tolerance:a prospective study among Japanese Americans[J]. Diabetes Care,2003,26(3):650-655. doi: 10.2337/diacare.26.3.650 [4] 任晨曦, 张婕, 徐佰慧, 等. 中年人内脏脂肪含量与2型糖尿病的相关性研究; proceedings of the 中华医学会第十一次全国内分泌学学术会议, 中国广东广州, F, 2012 [C]. [5] 糖尿病的诊断标准[J]. 中国慢性病预防与控制, 2009, 17(2): 129. [6] Ma R C,Chan J C. Type 2 diabetes in East Asians:Similarities and differences with populations in Europe and the United States[J]. Ann N Y Acad Sci,2013,1281(1):64-91. doi: 10.1111/nyas.12098 [7] Dale C E,fatemifar G,palmer T M,et al. Causal associations of adiposity and body fat distribution with coronary heart disease,stroke subtypes,and type 2 diabetes mellitus:A mendelian randomization analysis[J]. Circulation,2017,135(24):2373-2388. doi: 10.1161/CIRCULATIONAHA.116.026560 [8] Zheng R,cao L,cao W,et al. Risk factors for hypogonadism in male patients with type 2 diabetes[J]. J Diabetes Res,2016,2016:5162167. [9] Kuwahara K,honda T,nakagawa T,et al. Body mass index trajectory patterns and changes in visceral fat and glucose metabolism before the onset of type 2 diabetes[J]. Sci Rep,2017,7:43521. doi: 10.1038/srep43521 [10] 谭擎缨,姚佳琦,王秀景,等. 腹腔内脏脂肪面积与2型糖尿病及血清胰岛素的相关研究[J]. 东南国防医药,2015,17(1):12-15. doi: 10.3969/j.issn.1672-271X.2015.01.004 [11] Bodis K,roden M. Energy metabolism of white adipose tissue and insulin resistance in humans[J]. Eur J Clin Invest,2018,48(11):e13017. doi: 10.1111/eci.13017 [12] 刘娟,马建,王洋,等. 胰岛素抵抗与脂肪细胞因子关系及其产生机制研究[J]. 中医药临床杂志,2017,29(1):9-12. [13] 程莉,程纤,易志刚. 2型糖尿病患者的腹腔内脂肪面积及其与胰岛素敏感性、血清炎症因子和脂肪因子的相关性[J]. 广西医学,2020,42(23):3043-3046. [14] 焦阳,关锐,彭彦平,等. 血清脂质代谢指标水平、内脏脂肪面积与糖代谢异常合并肥胖的相关性研究[J]. 国际检验医学杂志,2021,42(4):489-492. doi: 10.3969/j.issn.1673-4130.2021.04.024 [15] 孙玉萍,陆影,高新,等. 汉族、维吾尔族和哈萨克族人群内脏脂肪素水平与尿酸、脂代谢指标的相关性[J]. 临床检验杂志,2015,33(4):258-261. [16] 郭星荣,王民登,韦一民,等. 桂西壮族2型糖尿病合并脑梗死与Hcy、CysC、内脏脂肪面积的相关性研究[J]. 右江医学,2016,44(6):618-620. doi: 10.3969/j.issn.1003-1383.2016.06.004